secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0000950170-24-044497
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics completes dosing of cohort 3 for SAB-142 Phase 1 trial; no serum sickness observed
--------------------------------------------------------------------------------

- Completed dosing of cohort 3 in Phase 1 trial of SAB-142.
- No instances of serum sickness reported.
- Company to issue corporate update press release on or about April 16, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024044497/0000950170-24-044497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024044497/sabs-20240412.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-044497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer